PET/CT Imaging for Amyloid in CAPS on Anakinra
Part of Genetic & congenital, Hormones & metabolism, Immune system & allergy, Skin clinical trials.
This trial uses a special PET/CT scan to see if a radioactive tracer can measure changes in amyloid buildup in people with CAPS who have developed a skin reaction to anakinra. It may help doctors understand how the disease is affecting your organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are currently in another NIH study for CAPS (protocol 17-I-0016) and have been diagnosed with MWS or NOMID.
- You agree to share your data from this study with that other NIH study.
- You have developed thickened skin where you get your anakinra injections.
- If you can become pregnant or get someone pregnant, you agree to use two effective birth control methods (one barrier method) starting 28 days before the scan and continuing for 90 days after.
- You are not pregnant or breastfeeding, and you are not on dialysis or taking blood thinners like heparin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This Phase 2 study tests an iodine-based scan medicine to help learn how systemic amyloidosis affects the body and organs. It may help doctors better characterize the disease using specific imaging tests.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study uses PET/CT scans to look at the heart in people who carry a genetic change (TTR mutation) that can cause a heart condition called amyloidosis, and compares them with people who have symptoms and healthy controls. It may help doctors better understand and detect the disease earlier.
This study tests a new imaging agent that helps doctors see amyloid buildup in the heart using a PET scan. It may help diagnose cardiac amyloidosis more accurately and guide treatment decisions.
This study uses an amyloid PET/CT scan to see how well first-line treatment is working in people with AL cardiac amyloidosis, a condition where abnormal proteins build up in the heart. The scan may help doctors better understand and monitor the disease.
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.